New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss ...
Amgen’s stock slides 7.8% after weight-loss drug data lags analyst expectations
Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
BioSpace8h
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...
Amgen Says Its Weight Loss Drug Candidate MariTide Reduced Weight Up To 20 Percent In Phase 2 Study
Tuesday reported encouraging results from its Phase 2 study of MariTide in people with obesity. Results from the 2 ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...